TRON is involved in two projects of a new Collaborative Research Center

In the course of evolution, the immune system has developed sophisticated mechanisms to identify and eliminate invading pathogens and degenerate cells, thereby preventing infection and tumor occurrence. When these mechanisms are ineffective or somehow bypassed, tumors or chronic infections may form. Clarifying the processes leading to ineffective immune defense is the central goal of the

Continue Reading

Honorary Medical Doctor’s Degree for Cornelis Melief

Mainz, 2017-10-25 – TRON scientific advisor Prof. Dr. Dr. Cornelis J. Melief, Leiden, Netherlands, will be awarded with the degree of an honorary medical doctor. Melief will be awarded for his lifetime achievements as a pioneer of tumor immunology, as well as for his commitment and deserts regarding immunological research in Mainz. Further information about

Continue Reading

Neue Krebsimmuntherapien – Ugur Sahin im Expertengespräch

Was versprechen neuartige personalisierte Krebsimmuntherapien? Wie können Patienten von Ihnen profitieren, und welche Risiken bergen die Behandlungen? Zwei neue Ansätze in der Krebsimmuntherapie sind die CAR-T-Methode und die so genannten Neoantigen-Vakzine. Beide werden gerade getestet und sind sehr vielversprechend. Der regionale Radiosender SWR2 sendete hierzu einen Radiobeitrag in seinem Programm. Einen Mitschnitt sowie ein Transkript

Continue Reading

Improvement of in vivo expression of genes delivered by self-amplifying RNA using Vaccinia Virus immune evasion proteins

Among nucleic acid-based delivery platforms, self-amplifying RNA (saRNA) vectors are of increasing interest for applications such as transient expression of recombinant proteins and vaccination. Although saRNA is a promising technology, antigen expression from saRNA is limited by the host cells’ innate interferon response. TRON’s Tim Beissert and colleagues show, in an upcoming issue of Human

Continue Reading

Elimination of large tumors in mice by mRNA-encoded bispecific antibodies

Mainz, June 2017 – We are pleased to announce that our close cooperation partner BioNTech has today published an article in Nature Medicine. The paper entitled “Elimination of large tumors in mice by mRNA-encoded bispecific antibodies” reports preclinical data featuring their novel class of mRNA-encoded antibody drugs called RiboMABs® and describes the application of their

Continue Reading

Special Issue Frontiers in Immunology

Mainz, 20. December 2016 – TRON scientists kick off special issue in Frontiers in Immunology. This is a call for papers to provide an up-to-date overview of current efforts to understand the immunological mechanisms of neoantigen directed T-cell immunity and the attempts to harvest this source of antigens for cancer immunotherapy. Read more about the

Continue Reading

11 Fakten über Krebs

Mainz, 23. November 2016 – Wie entstehen Krebszellen? Ist Krebs erblich? Warum ist es so schwer, Krebs zu behandeln/zu heilen und welche neuen Ansätze zur Krebsbehandlung gibt es? Welche Rolle spielt dabei die individualisierte Immuntherapie – und was ist das überhaupt? TRON und BioNTech tragen 11 Fakten über Krebs zu “Wissen im Herzen” bei, eine

Continue Reading